Related Experiment Videos
[Subacute Budd-Chiari syndrome treated with rTPA. Considerations on a case]
A Nardini1, E Falco, G Celoria
1II Divisione di Chirurgia Generale, Ospedale Civile Sant'Andrea, La Spezia.
Minerva Chirurgica
|October 15, 1993
Summary
Recombinant Tissue Plasminogen Activator (rTPA) offers a new treatment for Budd-Chiari syndrome (BCS). This therapy shows promise as a standalone or supportive treatment for BCS patients.
Area of Science:
- Hepatology
- Vascular Medicine
- Thrombotic Disorders
Background:
- Budd-Chiari syndrome (BCS) is a rare condition characterized by hepatic vein obstruction.
- Traditional medical therapies for BCS have demonstrated limited efficacy.
- Surgical interventions are often employed but carry significant risks.
Observation:
- This report details a successful case of Budd-Chiari syndrome treated with recombinant Tissue Plasminogen Activator (rTPA).
- The study reviews the known etiology and symptomatology of BCS.
- Existing treatment modalities for BCS are discussed.
Findings:
- Recombinant Tissue Plasminogen Activator (rTPA) demonstrated effectiveness in treating hepatic vein thrombosis.
- rTPA may serve as a primary therapeutic option in select BCS cases.
- The fibrinolytic agent can be used as a bridge to surgery or for non-surgical candidates.
Implications:
- rTPA presents a potential advancement in managing Budd-Chiari syndrome.
- This therapeutic approach could improve outcomes for BCS patients.
- Further research into rTPA's role in BCS is warranted.